Australia's Cogstate climbs on revenue growth

Cogstate

21/04/2022 01:47

** Shares of neuroscience tech firm Cogstate Ltd  CGS.AX 
rise as much as 5% to A$2.31, on course for their best session
since April 13, if gains hold 
    ** Reports Q3 revenue of A$9.3 million ($6.92 million), a 5%
growth, driven by clinical trials revenue mostly related to
Alzheimer's disease trials  urn:newsml:reuters.com:*:nASX650sP0 
    ** Maintains FY22 revenue guidance of A$44 million to A$47
million 
    ** CGS down 9.1% YTD, as of last close 

($1 = 1.3448 Australian dollars)

 (Reporting by Harshita Swaminathan)
 ((Harshita.Swaminathan@thomsonreuters.com))